First Ischemic Stroke
Conditions
Brief summary
Non-fasting triglyceride levels are thought to play a role in stroke. The investigators hypothesise that the results of a standardised oral triglyceride tolerance test in the subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of recurrent stroke within 12 months after the index event.
Detailed description
Since high postprandial triglycerides levels may be a risk factor for stroke, we use a combined oral triglyceride and glucose tolerance test in patients who had a first ischemic stroke. Follow-up after one year primarily assesses wether or not a recurrent stroke has occured. The glucose tolerance test is meant to identify patients with metabolic syndrome (and diabetes), since this condition is per se associated with increased levels of triglycerides. Potentially, the post-challenge triglyceride levels only play a role in patients without diabetes or metabolic syndrome. For further details see Ebinger et al. 'The Berlin 'Cream&Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in patients after acute ischaemic stroke', IJS; 2010,5, 47-51.
Interventions
OTHERoral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)
see Ebinger et al., IJS, 2010
Sponsors
University Hospital, Saarland
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years * First ischemic stroke * Incidence within less than 7 days * Informed consent obtained
Exclusion criteria
* Aphasia (if hampering informed consent) * Swallowing disorder * Pregnancy * Renal or hepatic failure * Pancreatitis * Cholecystolithiasis * Malabsorption * Lactose intolerance * Psychosis * Drug and/or alcohol addiction * Expected life expectancyr12 months * Inability to sign informed consent * Acute coronary syndrome * Severe heart valve disorder * Heart failure (NYHA III-IV) * Severe infectious/rheumatic disease * Sever metabolic disease * No oral glucose tolerance test in case of known diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrent Stroke | outcome measure is assessed one year after first ischemic stroke. | The primary end-point of the study is a recurrent fatal or nonfatal stroke within the first 12 months after the event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MI | one year after first ischemic stroke | Myocardial infarction |
| death | one year after first ischemic stroke | cardiovascular death (death due to any cardiovascular or cerebrovascular event) |
| TIA | one year after first ischemic stroke | transient ischemic attack |
Countries
Germany
Outcome results
None listed